Patient, Oncologist, and Payer Preferences for Adjuvant Endocrine Therapy and CDK4/6 Inhibitor Regimens in Early-Stage Breast Cancer: A Discrete Choice Experiment

Autor: Beusterien K, Maculaitis MC, Hallissey B, Gaschler MM, Smith ML, Law EH

Publikováno v: Patient Preference and Adherence, Vol Volume 15, Pp 611-623 (2021)

Kathleen Beusterien,1 Martine C Maculaitis,2 Bernadette Hallissey,1 Michael M Gaschler,2 Mary Lou Smith,3 Ernest H Law4 1Kantar, Health Division, Horsham, PA, USA; 2Kantar, Health Division, New York, NY, USA; 3Research Advocacy Network, Plano, TX, US

Externí odkaz: https://doaj.org/article/3c98701d94a944aa9c32c4cecb4a0f68

Oncologist and Patient Preferences for Attributes of CDK4/6 Inhibitor Regimens for the Treatment of Advanced/Metastatic HR Positive/HER2 Negative Breast Cancer: Discrete Choice Experiment and Best–Worst Scaling

Autor: Maculaitis MC, Liu X, Will O, Hanson M, McRoy L, Berk A, Crastnopol M

Publikováno v: Patient Preference and Adherence, Vol Volume 14, Pp 2201-2214 (2020)

Martine C Maculaitis,1 Xianchen Liu,2 Oliver Will,3 Madelyn Hanson,4 Lynn McRoy,2 Alexandra Berk,1 Melissa Crastnopol3 1Kantar, Health Division, New York, NY, USA; 2Pfizer Oncology, Pfizer Inc, New York, NY, USA; 3Kantar, Health Division, Horsham, PA

Externí odkaz: https://doaj.org/article/13af3594502a474b9593f9267ee21024

PCR89 The Burden of High-Risk Non-Muscle Invasive Bladder Cancer Among Patients Treated with Bacillus Calmette-Guerin

Autor: Kopenhafer, L, Chang, J, Thompson, A, Sikirica, S, Masters, ET, Cappelleri, JC, Peck, EY, Maculaitis, MC

Publikováno v: In Value in Health July 2022 25(7) Supplement:S557-S557

Preferences for a Clostridioides difficile vaccine among adults in the United States.

Autor: Vietri J; Pfizer Inc, 500 Arcola Road, Collegeville, PA 19426, USA. Electronic address: Jeffrey.Vietri@pfizer.com., Maculaitis MC; Oracle Life Sciences, 2300 Oracle Way, Austin, TX 78741, USA. Electronic address: Martine.Maculaitis@oracle.com., Cappelleri JC; Pfizer Inc, 445 Eastern Point Road, Groton, CT 06340, USA. Electronic address: Joseph.C.Cappelleri@pfizer.com., Yu H; Pfizer Inc, 500 Arcola Road, Collegeville, PA 19426, USA. Electronic address: Holly.Yu@pfizer.com., Kopenhafer L; Oracle Life Sciences, 2300 Oracle Way, Austin, TX 78741, USA. Electronic address: Lewis.Kopenhafer@oracle.com., Beusterien K; Oracle Life Sciences, 2300 Oracle Way, Austin, TX 78741, USA. Electronic address: Kathleen.Beusterien@oracle.com.

Publikováno v: Vaccine [Vaccine] 2024 Oct 24; Vol. 42 (24), pp. 126261. Date of Electronic Publication: 2024 Aug 31.

A latent class analysis of factors influencing preferences for infant respiratory syncytial virus (RSV) preventives among pregnant people in the United States.

Autor: Maculaitis MC; Real World Data & Analytics, Oracle Life Sciences, Austin, TX, USA., Hauber B; Worldwide Medical and Safety, Pfizer Inc, New York, NY, USA., Beusterien KM; Real World Data & Analytics, Oracle Life Sciences, Austin, TX, USA., Will O; Real World Data & Analytics, Oracle Life Sciences, Austin, TX, USA., Kopenhafer L; Real World Data & Analytics, Oracle Life Sciences, Austin, TX, USA., Law AW; Global Access & Value Pfizer Inc, New York, NY, USA., Vietri JT; Global Access & Value, Pfizer Inc, Collegeville, PA, USA., Cappelleri JC; Statistical Research and Data Science Center, Pfizer Inc, Groton, CT, USA., Coulter JR; Worldwide Medical and Safety, Pfizer Inc, New York, NY, USA., Pugh S; US Vaccines Medical & Scientific Affairs, Pfizer Inc, New York, NY, USA., Shea KM; Global Access & Value Pfizer Inc, New York, NY, USA.

Publikováno v: Human vaccines & immunotherapeutics [Hum Vaccin Immunother] 2024 Dec 31; Vol. 20 (1), pp. 2358566. Date of Electronic Publication: 2024 Jun 07.